« Back

William Lis

Independent Director

William Lis joined our Board in 2018 and serves as a member of the Nominating and Corporate Governance Committee. Mr. Lis brings to our Board over 30 years of experience in the biopharmaceutical industry, at both the executive and board level, including considerable leadership and business, financial, and product development expertise.

Mr. Lis currently serves as Chief Executive Officer and a member of the Board of Tr1x Biotherapeutics, Inc. Previously, he held various executive and board level positions at Jasper Therapeutics, Inc. (Nasdaq) from 2019 to 2023, including Chief Executive Officer and Executive Chairman of the Board; at Eidos Therapeutics, Inc. (Nasdaq), where he served on the Board from 2018 until its acquisition by Bridge Bio Pharma Inc. in 2021; and at Portola Pharmaceuticals, Inc. (Nasdaq) from 2008 to 2020, including Chief Executive Officer and member of the Board of Directors, Chief Operating Officer, and Chief Business Officer. Prior to these roles, he held various executive positions at Scios, Inc. (a Johnson & Johnson company) from 2003 to 2008, including as Senior Vice President of New Product Development and Business Development, and various roles of increasing responsibility at Millennium Pharmaceuticals, Inc. (previously COR Therapeutics, Inc.) from 1998 to 2003 in sales, marketing, medical affairs, and business development.

Mr. Lis received a B.S. from the University of Maryland.

Independent Director